Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification ...

Researchers have found in a new research that children with inflammatory skin conditions such as atopic dermatitis, psoriasis ...

The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) for chronic ...

Hives usually do not break the skin, but bleeding can occur if a person ... or tests for celiac disease or thyroid problems. If the hives are not always apparent, it may help for a person to ...

The FDA has approved the popular drug Dupixent (generic name, dupilumab) for adults and kids 12 and up with chronic spontaneous urticaria (CSU), a long-lasting itchy skin condition, when regular ...

Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden and debilitating hives and recurring itch.

There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and ...

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...

Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...